Prehospital epinephrine may reduce biphasic reaction and decrease ED length of stay in pediatric anaphylaxis patients: Study

Prehospital epinephrine may reduce biphasic reaction and decrease ED length of stay in pediatric anaphylaxis patients suggests a study published in the Annals of Allergy, Asthma & Immunology.

Prompt epinephrine administration is important to improve outcomes in anaphylaxis. The objective of our study was to assess the impact of prehospital epinephrine on clinical outcomes of hospital admission, biphasic reactions, and ED length of stay (LOS) in a cohort of ED anaphylaxis patients including both children and adults. They conducted a single-center prospective and retrospective cohort study of anaphylaxis patients from April 2008 to December 2022. Associations between prehospital epinephrine administration with biphasic reactions and ED LOS were assessed with univariable models and the association with ED disposition was assessed with both univariable and multivariable logistic regression.

Results: A total of 1107 patient visits were included for analysis. The median patient age was 29 (IQR 14-50), 593 (53.6%) patients were female, 366 (33.1%) were under 18 years of age. Patients in the prehospital epinephrine group were also less likely to experience a biphasic reaction (5.4% vs 9.3%; OR 0.56, 95% CI 0.34–0.92) and had a decreased ED LOS (median 4.0 hours vs 4.7 hours). There was no difference in hospital admission between patients with and without prehospital epinephrine in both the univariable (19.5% vs 15.7%; OR 1.30, 95% CI: 0.94–1.79) and multivariable (aOR 1.08, 95% CI: 0.71-1.64) models. Prehospital epinephrine administration reduced the odds of a biphasic reaction and decreased ED LOS but did not reduce hospitalization in this cohort of ED anaphylaxis patients. Our findings suggest that timely administration of prehospital epinephrine is associated with improved patient outcomes.

Keywords:



Reference:

Andrea L. Hlady, Aliza F. Weinman, Yuedan Zhang, Aidan F. Mullan, Ronna L. Campbell,

Outcomes Associated with Prehospital Epinephrine in Adult and Pediatric Anaphylaxis Patients. Annals of Allergy, Asthma & Immunology. 2024. ISSN 1081-1206,

https://ift.tt/zrpC3sV.

(https://ift.tt/j4zX1WR)


Keywords:

Prehospital, epinephrine, reduce, biphasic, reaction, decrease, ED, length of stay, pediatric, anaphylaxis, patients, study, Anaphylaxis; Emergency Department; Epinephrine; Prehospital Treatment; Pediatric; Biphasic; Hospitalization






from Medical News, Health News Latest, Medical News Today - Medical Dialogues | https://ift.tt/AHdDLs3

Comments

Post a Comment

Popular posts from this blog

'Details sought include Third-party info, hence exempted under RTI Act': NMC on RTI query on Faculty Gap in Medical Colleges

Image
New Delhi:  Stating that the details sought under the RTI includes third-party information, the National Medical Commission (NMC) has refused to disclose the names of the medical colleges that fell short on faculty counts and other teaching infrastructure. Recently activist Dr. KV Babu filed an application under the Right to Information Act seeking the details of the notices issued by the NMC Undergraduate Medical Education Board (UGMEB) to the medical colleges for deficiencies in Clinical Material and staff during the period from 01/01/2023 to 30/04/2024. He also sought to know the details of the fine imposed or the action taken by the NMC UG Board from 01/01/2023 to 30/04/2024. In response, the Apex medical regulatory body in India has said that the concerned information includes third party information. "Since the information sought by you, includes third party information, hence the same is exempted for as per Section 8(1) (j) of the Right to Information Act, 2005," th...
Read more

Zasocitinib therapy highly efficacious for treatment of severe plaque psoriasis: JAMA

Image
A recent study published in the Journal of American Medical Association revealed that Zasocitinib could be a breakthrough in the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin condition characterized by red, scaly patches, affects millions throughout the globe. While several treatments exist, the demand for new, effective, and well-tolerated oral therapies remains high. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, emerges as a promising candidate to meet this need. This trial was conducted between August 2021 and September 2022 across 55 centers in the US and Canada and found that Zasocitinib not only significantly improved skin clearance in patients but also expressed a favorable safety and tolerability profile. The study enrolled a total of 287 participants aged between 18 and 70 years, each with a Psoriasis Area and Severity Index (PASI) score of 12 or greater, a Physician’s Global Assessment score of 3...
Read more

New wearable laser device may monitor brain blood flow to gauge stroke risk, reports research

Image
Researchers have developed a laser-based device that can be placed on the head to non-invasively monitor changes in brain blood flow and volume. The new device could one day help save lives by offering a direct and simple way to assess stroke risk based on physiological markers rather than indirect markers like lifestyle factors. Strokes occur when blood flow to the brain is blocked or reduced, causing debilitating brain cell damage. With about 15 million people worldwide affected by strokes each year, it is the second leading cause of death and a leading cause of long-term disability. “The lack of a cost-effective and scalable stroke risk assessment system complicates long-term stroke prevention because a physician can’t tell whether a patient’s risk is stable or worsening,” said research team member Simon Mahler, a postdoctoral scholar in Changhuei Yang’s laboratory at the California Institute of Technology. “This new method could help catch early signs of increased stroke risk, w...
Read more